Futu News, January 21, Fosun Pharmaceutical announced that on January 7, the holding subsidiary Fosun Pharmaceutical Industry signed a “sub-license agreement” with MPP on matters such as authorizing production of the COVID-19 oral drug Molnupiravir. This license is a non-exclusive license; the licensing area is 105 low- and middle-income countries/regions such as India, Pakistan, and Côte d'Ivoire, excluding China.

Prior to commercial production of cooperative drugs, relevant technology handover needs to be completed, and production facilities must be approved by SRA or WHOPQ certified. The production, sale, etc. of cooperative drugs within the region must be approved by the relevant competent authorities (including but not limited to marketing approval) before implementation.

As of the date of this announcement, the Group has not received orders for cooperative drugs and has not yet carried out related production. The impact on the Group's current and future revenue and profits cannot be predicted.